World Health Organization. BCG vaccine. WHO position paper. Wkly Epidemiol Rec. 2004;79(4):27-38.
2.
CalmetteAGuerinC. Sur quelques propriétés du bacille tuberculeux d’origine, cultivé sur la bile de boeuf glycérinée. C R Acad Sci. 1909;149:716-718.
3.
HsuTHingley-WilsonSMChenB. The primary mechanism of attenuation of bacillus Calmette-Guerin is a loss of secreted lytic function required for invasion of lung interstitial tissue. Proc Natl Acad Sci U S A. 2003;100:12420-12425.
4.
RosenthalSRLoewinsohne, GrahamMLLiverightDThorneGJohnsonV. BCG vaccination against tuberculosis in Chicago. A twenty-year study statistically analyzed. Pediatrics. 1961;28:622-641.
5.
PereiraSMBarretoMLPilgerD. Effectiveness and cost-effectiveness of first BCG vaccination against tuberculosis in school-age children without previous tuberculin test (BCG-REVAC trial): a cluster-randomized trial. Lancet Infect Dis. 2012;12:300-306.
6.
RodriguesLCMangtaniPAbubakarI. How does the level of BCG vaccine protection against tuberculosis fall over time?BMJ. 2011;343:d5974.
7.
YamamotoSYamamotoT. Historical review of BCG vaccine in Japan. Jpn J Infect Dis. 2007;60:331-336.
8.
MilstienJBGibsonJJ. Quality control of BCG vaccine by WHO: a review of factors that may influence vaccine effectiveness and safety. Bull World Health Organ. 1990;68:93-108.
9.
LotteAWasz-HockertOPoissonNDumitrescuNVerronMCouvetE. BCG complications. Estimates of the risks among vaccinated subjects and statistical analysis of their main characteristics. Adv Tuberc Res. 1984;21:107-193.
10.
LotteAWasz-HockertOPoissonN. Second IUATLD study on complications induced by intradermal BCG-vaccination. Bull Int Union Tuberc Lung Dis. 1988;63:47-59.
11.
ClementsCJ, ed. Supplementary Information on Vaccine Safety: Part 2: Background and Rates of Adverse Events Following Immunization. Geneva, Switzerland: Department of Vaccines and Biologicals, World Health Organization; 2000.
